206. 脆弱Ｘ症候群 Fragile X syndrome Clinical trials / Disease details

臨床試験数 : 104 / 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79

diseases per page:

Showing 1 to 10 of 104 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04823052 (ClinicalTrials.gov)	January 2022	24/3/2021	Investigation of Sulindac in Male Fragile X Syndrome Patients Aged 13-40	A Phase IIa, Double-blind, Placebo-controlled Adaptive Design Study to Explore the Safety and Effica ...	Fragile X Syndrome	Drug: Sulindac , dose strength 1;Drug: Sulindac , dose strength 2;Drug: Placebo	Healx Limited	NULL	Not yet recruiting	13 Years	40 Years	Male	36	Phase 2	United States
2	NCT05120505 (ClinicalTrials.gov)	December 29, 2021	3/11/2021	Metformin in Children With Fragile X Syndrome	Efficacy and Safety of Metformin in the Treatment of Fragile X Syndrome	Fragile X Syndrome;Metformin	Drug: Metformin;Drug: Placebo	Children's Hospital of Fudan University	NULL	Recruiting	2 Years	16 Years	All	20	Phase 4	China
3	NCT05163808 (ClinicalTrials.gov)	December 15, 2021	15/12/2021	A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male ...	Fragile X Syndrome	Drug: zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Not yet recruiting	12 Years	18 Years	Male	150	Phase 2/Phase 3	NULL
4	NCT05030129 (ClinicalTrials.gov)	September 15, 2021	5/8/2021	Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Sy ...	An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in ...	Fragile X Syndrome	Dietary Supplement: 5-Hydroxytryptophan / Vitamin B6;Drug: Ergoloid Mesylate;Other: Placebo	Elizabeth Berry-Kravis	NULL	Not yet recruiting	18 Years	45 Years	Male	15	Phase 2	NULL
5	NCT04977986 (ClinicalTrials.gov)	September 13, 2021	20/7/2021	Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 ...	Fragile X Syndrome	Drug: ZYN002 - transdermal gel;Drug: Placebo	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	3 Years	17 Years	All	204	Phase 3	United States;Australia;Ireland;United Kingdom
6	NCT04314856 (ClinicalTrials.gov)	January 12, 2021	11/3/2020	Novel Clinical Target in Fragile X Syndrome	Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome	Fragile X Syndrome (FXS)	Drug: 18F-FTC-146	Guido A. Davidzon, MD, MS	NULL	Recruiting	18 Years	65 Years	All	20	Phase 1	United States
7	NCT04141163 (ClinicalTrials.gov)	October 29, 2019	24/10/2019	Metformin in Patients With Fragile X	A Parallel Group Design Randomized Double-Blind Trial of Metformin Treatment in Patients With Fragil ...	Fragile X Syndrome	Drug: Metformin;Drug: Placebo oral tablet	Rowan University	FRAXA Research Foundation;University of Pennsylvania	Recruiting	18 Years	50 Years	Male	40	Phase 1/Phase 2	United States
8	NCT03862950 (ClinicalTrials.gov)	May 24, 2019	26/2/2019	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)	A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)	Fragile X Syndrome;Fragile X Mental Retardation Syndrome;Mental Retardation, X-Linked;Genetic Diseas ...	Drug: Placebo Medication;Drug: Metformin	University of Alberta	St. Justine's Hospital	Recruiting	6 Years	35 Years	All	120	Phase 2	Canada
9	NCT03802799 (ClinicalTrials.gov)	November 9, 2018	26/12/2018	Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adole ...	An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered ...	Fragile X Syndrome	Drug: ZYN002 - CBD Transdermal Gel	Zynerba Pharmaceuticals, Inc.	NULL	Enrolling by invitation	3 Years	18 Years	All	300	Phase 2/Phase 3	United States;Australia;New Zealand
10	NCT03697161 (ClinicalTrials.gov)	September 17, 2018	1/10/2018	A Study of OV101 in Individuals With Fragile X Syndrome	A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and E ...	Fragile X Syndrome (FXS)	Drug: OV101 (gaboxadol)	Ovid Therapeutics Inc.	NULL	Completed	13 Years	22 Years	Male	23	Phase 2	United States

First Previous1 2 3 4 5…11Next Last